Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with cediranib or olaparib
549.0
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with cediranib or olaparib
680.0
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with cediranib and olaparib
126.0
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with olaparib and atezolizumab
72.0
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with olaparib or cediranib
132.0
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with olaparib or AT13387
40.0
Pregnant women are excluded; breastfeeding should be discontinued if the mother is treated with cediranib and olaparib
70.0
